Consensus symposium on combined antiviral therapy

Antiviral Research

Volumn 29, Issue 1, 1996, Pages 5-29

  De Jong, Menno D ^a,g   Boucher, Charles A B ^b   Galasso, George J ^c   Hirsch, Martin S ^d   Kern, Earl R ^e   Lange, Joep M A ^a   Richman, Douglas D ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPRENAVIR; ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ZIDOVUDINE TRIPHOSPHATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS; DRUG POTENTIATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; RHINOVIRUS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; VIRUSES;

EID: 0029871192     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00910-8     Document Type: Review

References (126)

1. Anton, E.D., Bacheler, L., Garber, S., Reid, C., Buckery, R., Scarnati, H., Korant, B. and Winslow, D.L. (1995) Replicative ability of HIV variants with substitutions in the active site of protease is dependent on compensatory mutations outside the active site. IVth International Workshop on HIV Drug-resistance, Sardinia. Abstract 60.
2. Ashman, C., Larkin, D., Cammark, N., Boehme, R.E. and Cameron, J.M. (1994) Lamivudine inhibits hepatitis B virus (HBV) production in the HBV transfected cell line 2.2.15. VIth International Symposium on Viral Hepatitis, Madrid. Abstract 65.
3. Aurelius, E., Johansson, B., Skoldenberg, B., Staland, A. and Forsgren, M. (1991) Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 337, 189-192.
4. Beloqui, O., Prieto, J., Suarez, M., Gil, B., Qian, C.H., Garcia, N. and Civeira, M.P. (1993) N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J. Interferon Res. 13, 279-282.
5. Benhamou, Y., Dohin, E., Lunel-Fabiani, F., Poynard, T., Huraux, J.M., Katlama, C., Opolon, P. and Gentilini, M. (1995) Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345, 396-397.
6. Betageri, G.V., Szebeni, J., Hung, K., Patel, S.S., Wahl, L.M., Corcoran, M. and Weinstein, J.N. (1990) Effect of dipyridamole on transport and phosphorylation of thymidine and 3′-azido-3-deoxythymidine in human monocyte/macrophages. Biochem. Pharmacol. 40, 867-870.
7. Biron, F., Lucht, F., Peyramond, D., Fresard, A., Vallet, T., Nugier, F., Grange, J., Malley, S., Hamedi-Sangsari, F. and Vila, J. (1995) Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1 infected individuals. J. Acq. Immune Def. Syndr. Hum. Retrovir. 10, 36-40.
8. Biron, K.K., Stanta, S.C., Sorrel, J.A., Fyfe, J.A., Killer, P.M., Lambe, C.U. and Nelson, D.J. (1985) Metabolic activation of the nucleoside analog 9-(1,3-dihydroxy)-2-propoxymethylguanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82, 2473-2477.
9. Boucher, C.A.B., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M.A. and Cameron, J.M. (1993) High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37, 2231-2234.
10. Brillanti, S., Garson, J., Foli, M., Whitby, K., Deaville, R., Masci, C., Miglioli, M. and Barbara, L. (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812-817.
11. Brook, M.G., Karayiannis, P. and Thomas, H.C. (1989) Which patients with chronic hepatitis B virus infection will respond to alfa-interferon therapy? A statistical analysis of predictive factors. Hepatology 10, 761-763.
12. Burger, D.M., Meenhorst, P.L., Koks, C.H.W. and Beijnen, J.H. (1993) Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob. Agents Chemother. 37, 1426-1431.
13. Camps, J., Garcia, N., Riezu-Boj, J.I., Civeira, M.P. and Prieto, J. (1993) Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J. Hepatol. 19, 408-412.
14. Cao, Y., Qin, L., Zhang, L. et al., (1995) Virologic and immunologic characterisation of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332, 201-208.
15. Chayama, K., Saitoh, S., Arase, Y., Ikeda, K., Matsumoto, T., Sakai, Y., Kobayashi, M., Unakami, M., Morinaga, T. and Kumada, H. (1991) Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 13, 1040-1043.
16. Coffin, J.M. (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489.
17. Collier, A.C., Coombs, R.W., Fischl, M.A., Skolnik, P.R., Northfelt, D., Boulin, P., Hooper, C.J., Kaplan, L.D., Volberding, P.A., Davis, L.G., Henrard, D.R., Weller, S. and Corey, L. (1993) Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann. Intern. Med. 119, 786-793.
18. Concorde Coordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343, 871-881.
19. Crump, C.E., Arruda, E. and Hayden, F.G. (1994) Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule. Antimicrob. Agents Chemother. 38, 1425-1427.
20. Davis, G.L., Balart, L.A., Schiff, E.R., Lindsay, K., Bodenheimer, H.C.J., Perrillo, R.P., Carey, W., Jacobson, I.M., Payne, J. and Dienstag, J.L. (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 321, 1501-1506.
21. De Miranda, P., Good, S., Yarchoan, R., Thomas, R.V., Blum, M.R., Myers, C.E. and Broder, S. (1989) Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin. Pharmacol. Ther. 46, 494-500.
22. Di Bisceglie, A.M., Fried, M.W., Swain, M.G., Bergasa, N.V., Yurdaydin, C., Simpson, L.H., Sallie, R., Conjeevaram, H., Kleiner, D., Park, Y. and Hoofnagle, J.H. (1993) Randomized, double blind placebo-controlled trial of ribavirin therapy for chronic hepatitis C. Hepatology 18, 93A.
23. Di Bisceglie, A.M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S.M. and Hoofnagle, J.H. (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321, 1506-1510.
24. Dienstag, J.L., Perrillo, R.P., Schiff, E.R., Bartholomew, M., Vicary, C. and Rubin, M. (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333, 1657-1661.
25. Dieterich, D.T., Poles, M.A., Lew, E.A., Mendez, P.E., Murphy, R., Addessi, A., Holbrook, J.T., Naughton, K. and Friedberg, D.N. (1992) Concurrent use of ganciclovir and foscarnet in treatment of cytomegalovirus infection in AIDS. J. Infect. Dis. 167, 1184-1188.
26. Doong, S.L., Tsai, C.H., Schinazi, R.F., Liotta, D.C. and Cheng, Y.C. (1991) Inhibition of the replication of of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88, 8495-8499.
27. Dornsife, R.E., St. Clair, M.H., Huang, A.T., Panella, T.J., Koszalka, G.W., Burns, C.L. and Averett, D.R. (1991) Anti-human immunodeficiency synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob. Agents Chemother. 35, 322-328.
28. Edlin, B.R., Weinstein, R.A., Whaling, S.M., Ou, C.Y., Connolly, P.J., Moore, J.L. and Bitran, J.D. (1992) Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. J. Infect. Dis. 165, 793-798.
29. Ehrlich, K.S., Mills, J., Chatis, P., Mertz, G.J., Busch, D.F., Follansbee, S.E., Grant, R.M. and Crumpacker, C.S. (1989) Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 320, 293-296
30. Emanuel, D., Cunningham, I., Jules-Elysee, K., Brochstein, J.A., Kernan, N.A., Laver, J., Stover, D., White, D.A., Fels, A., Polsky, B., Castro-Malaspina, H., Peppard, J.R., Bartus, P., Hammerling, U. and O'Reilly, R.J. (1988) Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immunoglobulin. Ann. Intern. Med. 109, 777-782.
31. Erice, A., Chou, S., Biron, K.K., Stanat, S.C., Balfour, H.H. and Jordan, M.C. (1989) Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320, 289-293.
32. Eron, J.J., Johnson, V.A., Merrill, D.P., Chou, T.-C. and Hirsch, M.S. (1992) Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother. 36, 1559-1562.
33. Fischl, M.A., Stanley, K., Collier, A.C., Arduino, J.M., Stein, D.S., Feinberg, J.E., Allan, J.D., Goldsmith, J.C. and Powderly, W.G. (1995) Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122, 24-32.
34. Freitas, V.R., Fraser-Smith, E.B. and Matthews, T.R. (1989) Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 12, 205-212.
35. Frissen, J.P.H., Van der Ende, M., Ten Napel, C.H., Weigel, H.M., Schreij, G.S., Kauffmann, R.H., Koopmans, P.P., Hoepelman, A.I., de Boer, J.B., Weverling, G.J., Haverkamp, G., Dowd, P., Miedema, F., Schuurman, R., Boucher, C.A.B. and Lange, J.M.A. (1994) Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. J. Infect. Dis. 169, 1351-1355.
36. Gallant, J.E., Moore, R.D., Richman, D.D., Keruly, J. and Chaisson, R.E. (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J. Infect. Dis. 166, 1223-1227.
37. Gao, W.Y., Johns, D.G. and Mitsuya, H. (1994) Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46, 767-772.
38. Gardner, M.B. (1991) Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 15, 267-286.
39. Gehrz, R.C., Nelson, C.M. and Kari, B.E. (1992) A combination of human cytomegalovirus (HCMV)-specific murine monoclonal antibodies exhibits synergistic antiviral activity in vitro. Antiviral Res. 17, 115-131.
40. Greco, W., Unkelbach, H.-D., Pöch, G., Sühnel, J., Kundi, M. and Bödeker, W. (1992) Consensus on concepts and terminology for combined-action assessment: the Saariselkä agreement. Arch. Complex Environ. Studies 4, 65-69.
41. Greco, W.R., Bravo, G. and Parsons, J.C. (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385.
42. Gruber, W.C., Wilson, S.Z., Throop, B.J. and Wyde, P.R. (1987) Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat. Pediat. Res. 21, 270-274.
43. Guffond, T., Dewilde, A., Lobert, P.E., Caparros-Lefebvre, D., Hober, D. and Wattre, P. (1994) Significance and clinical relevance of the detection of herpes simplex virus DNA by the polymerase chain reaction in cerebrospinal fluid from patients with presumed encephalitis. Clin. Infect. Dis. 18, 744-749.
44. Gwaltney, J.M. (1992) Combined antiviral and antimediator treatment of rhinovirus colds. J. Infect. Dis. 166, 776-782.
45. 3. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Abstract LB-1.
46. Hamzeh, F.M., Spector, T. and Lietman, P.S. (1993) 2-acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir. Antimicrob. Agents Chemother. 37, 602-604.
47. Haumont, M., Magdalou, J., Lafaurie, C., Ziegler, J.-M., Siest, G. and Colin, J.-N. (1990) Phenobarbital inducible UDP-glucuronosyl-transferase is responsible for glucuronidation of 3′-azido-3′-deoxythymidme: characterization of the enzym in human and rat liver microsomes. Arch. Biochem. Biophys. 281, 264-270.
48. Havlir, D., Cheeseman, S.H., McLaughlin, M., Murphy, R., Erice, A., Spector, S.A., Greenough, T.C., Sullivan, J.L., Hall, D., Myers, M., Lamson, M. and Richman, D.D. (1995) High dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171, 537-545.
49. Hayden, F.G. (1986) Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. 18 (suppl. B), 77-83.
50. Hedaya, M.A., Elmquist, W.F. and Sawchuk, R.J. (1990) Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm. Res. 7, 411-417.
51. Hendrix, C.W., Flexner, C., Szebeni, J., Kuwahara, S., Pennypacker, S., Weinstein, J.N. and Lietman, P.S. (1994) Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 38, 1036-1040.
52. Higgins, P.G., Barrow, G.I., Al-Nakib, W., Tyrrell, D.A.J., DeLong, D.C. and Lenox-Smith, I. (1988) Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res. 10, 141-149.
53. Ho, D.D., Hartshorn, K.L., Rota, T.R., Andrews, C.A., Kaplan, J.C., Schooley, R.T. and Hirsch, M.S. (1985) Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet i, 602-604.
54. Ho, D.D., Toyoshima, T., Mo, H., Kempf, D.J., Norbeck, D., Chen, C-M., Wideburg, N.E., Burt, S.K., Erickson, J.W. and Singh, M.K. (1994) Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68, 2016-2020.
55. Iino, S., Hino, K., Kuroki, T., Suzuki, H. and Yamamoto, S. (1993) Treatment of chronic hepatitis C with high-dose interferon alfa-2b. A multicenter study. Dig. Dis. Sci. 38, 612-618.
56. Johnson, V.A., Barlow, M.A., Merrill, D.P., Chou, T.C. and Hirsch, M.S. (1990) Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alfa. J. Infect. Dis. 161, 1059-1067.
57. Johnson, V.A., Merrill, D.P., Videler, J.A., Chou, T.-C. and Byrington, R.E. (1991) Two-drug combinations of zidovudine, didanosine and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164, 646-655.
58. Jouët, P., Roudot-Thoraval, F., Dhumeaux, D., Métreau, J.-M. and le groupe Francais pour l'étude du traîtement des hépatites chroniques NANB/C (1994) Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with Non-A, Non-B, C hepatitis. Gastroenterology 106, 686-690.
59. Kanai, K., Kako, M. and Okamoto, H. (1992) HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339, 1543.
60. Katzenstein, D., Hammer, S., Hughes, M., Gundacker, H., Jackson, B., Merigan, T., Hirsch, M. for the ACTG 175 Virology Team (1995) Plasma virion RNA in response to early antiretroviral drug therapy in ACTG 175: do changes in virus load parallel clinical and immunologic outcomes? 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Abstract LB-2.
61. Kern, E.R. (1990). Preclinical evaluation of antiviral agents. In: G.J. Galasso, T.C. Merigan and R.J. Whitley (Eds.), Antiviral agents and viral diseases of man, pp. 87-123, Raven Press, New York.
62. Kern, E.R. (1991) The value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant Proc. 23, 152-155.
63. Kornhauser, D.M., Petty, B.G., Hendrix, C.W., Woods, A.S., Nerhood, L.J., Bartlett, J.G. and Lietman, P.S. (1989) Probenecid and zidovudine metabolism. Lancet ii, 473-475.
64. Koskinas, K., Tibbs, C., Saleh, M.G., Pereira, L.M., McFarlane, I.G. and Williams, R. (1995) Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients. J. Med. Virol. 45, 29-34.
65. Kovacs, J.A., Baseler, M., Dewar, R.J., Vogel, S., Davey, R.J., Falloon, J., Polis, M.A., Walker, R.E., Stevens, R., Salzman, N.P., Metcalf, J.A., Masur, H. and Lane, H.C. (1995) Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332, 567-575.
66. Kozal, M.J., Shah, N., Yang, R., Shen, N., Fucini, R., Merigan, T.C., Richman, D.D., Chee, M.S. and Gingeras, T.R. (1995) Natural polymorphism of HIV-1 clade B protease gene and the implications for therapy. IVth International Workshop on HIV Drug-resistance, Sardinia. Abstract 76.
67. Kuppermann, B.D., Flores-Aguilar, M., Quinceno, J.I., Rickman, L.S. and Freeman, W.R. (1993) Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch. Opthalmol. 111, 1359-1366.
68. Lakeman, F., Blevins, B.S., Whitley, R. and Tolpin, M. (1991) In vitro neutralization of cytomegalovirus (CMV) strains by a human monoclonal antibody, MSL-109. Antiviral Res. 15 (suppl. 1), 77.
69. Lakeman, F.D. and Whitley, R.J. (1995) Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. J. Infect. Dis. 171, 857-863.
70. Lamarre, D., Doyon, L., Croteau, G., Pilote, L. and Thibeault, D. (1995) Molecular basis of HIV-1 resistance to protease inhibitors. Structural flexibility of the protease and second-site compensatory mutations in cleavage sites. IVth International Workshop on HIV Drug-resistance, Sardinia. Abstract 62.
71. Lane, H.C., Davey, V., Kovacs, J.A., Feinberg, J., Metcalf, J.A., Herpin, B., Walker, R., Deyton, L., Davet, R.T. and Falloon, J. (1990) Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann. Intern. Med. 112, 805-811.
72. Larder, B.A. (1994) Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75, 951-957.
73. Larder, B.A., Kemp, S.D. and Harrigan, P.R. (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699.
74. Lori, F., Malykh, A., Cara, A., Sun, D., Weinstein, J.N., Lisziewicz, J. and Gallo, R.C. (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266, 801-805.
75. Luciw, P.A., Pratt-Lowe, E., Shaw, K.E., Levy, J.A. and Cheng-Mayer, C. (1995) Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian-human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. USA 92, 7490-7494.
76. Machida, H., Nishitani, M. and Ashida, N. (1994) Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure. Microbiol. Immunol. 38, 109-115.
77. Madren, L.K., Shipman, C. and Hayden, F.G. (1995) In vitro inhibitory effects of combinations of anti-influenza agents. Antivir. Chem. Chemother. 6, 109-113.
78. Malley, S.D., Grange, J.M., Hamedi-Sangsari, F. and Vila, J.R. (1994) Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc. Natl. Acad. Sci. USA 91, 11017-11021.
79. Mansky, L.M. and Temin, H.R. (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69: 5087-5094.
80. Manischewicz, J.F., Quinnan, G.V., Lane, H.C. and Wittek, A.E. (1990) Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 34, 373-375.
81. Medina, D.J., Hsiung, G.D. and Mellors, J.W. (1992) Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Antimicrob. Agents Chemother. 36, 1127-1130.
82. Mellors, J.W., Kingsley, L.A., Rinaldo, C.R., Todd, J.A., Hoo, B.S., Kokka, R.P. and Gupta, P. (1995) Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122, 573-579.
83. Meng, T.-C., Fischl, M.A., Boota, A.M., Spector, S.A., Bennett, D., Bassiakos, Y., Lai, S., Wright, B. and Richman, D.D. (1992) Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann. Intern. Med. 116, 13-20.
84. Nájera, I., Holguín, A., Quiñones-Mateu, M.E., Muñoz-Fernández, M.A., Nájera, R., López-Galíndez, C. and Domingo, E. (1995) Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69, 23-31.
85. Najéra, I., Richman, D.D., Olivares, I., Rojas, J.M., Peinado, M.A., Perucho, M., Najéra, R. and López-Galíndez, C. (1994) Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses 10, 1479-1488.
86. Niu, J., Wang, Y., Dixon, R., Bowden, S., Qiao, M., Einck, L. and Locarnini, S. (1993) The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res. 21, 155-171.
87. Nokta, M.A., Tolpin, M.D., Nadler, P.I. and Pollard, R.B. (1994) Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL-109): Enhancement of in vitro foscarnet and ganciclovir induced inhibition of CMV replication. Antiviral Res. 24, 17-26.
88. Pantaleo, G., Menzo, S., Vaccaezza, M., Graziosi, C., Cohen, O.J., Demarest, J.F., Montefiori, D., Orenstein, J.M., Fox, C., Schrager, L.K., Margolick, J.B., Buchbinder, S., Giorgi, J.V. and Fauci, A.S. (1995) Studies in subjects with long-term non-progressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216.
89. Petty, B.G., Kornhauser, D.M. and Lietman, P.S. (1990) Zidovudine with probenecid: a warning. Lancet i, 1044-1045.
90. Pluda, J.M., Cooley, T.P., Montaner, J.S., Shay, L.E., Reinhalter, N.E., Warthan, S.N., Ruedy, J., Hirst, H.M., Vicary, C.A., Quinn, J.B., Yuen, G.J., Wainberg, M.A., Rubin, M. and Yarchoan, R. (1995) A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171, 1438-1447.
91. Pollard, R.B. and Nokta, M.A. (1992) An anti-cytomegalovirus human monoclonal antibody in individuals with AIDS: A phase I/II study. Antiviral Res. 16 (Suppl. 1), 111.
92. Rajaonarison, J.F., Lacarelle, B., Catalin, J., Placidi, M. and Rahmani, R. (1992) 3′-azido-3′-deoxythymidine drug interactions. Screening for inhibitors in human liver microsomes. Drug Metab. Disp. 20, 578-584.
93. Rajaonarison, J.F., Lacarelle, B., De Sousa, G., Catalin, J. and Rahmani, R. (1991) In vitro glucuronidation of 3′-azido-3′-deoxythymidine by human liver, Role of UDP-glucuronosyltransferase 2 form. Drug Metab. Dispos. 19, 809-815.
94. Reardon, J.E. (1992) Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics and nucleotide incorporation. Biochemistry 1992; 31: 4473-4479.
95. Reed, E.C., Bowden, R.A., Dandliker, P.S., Lilleby, K.E. and Meyers, J.D. (1988) Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109, 783-788.
96. Reichard, O., Andersson, J., Schvarcz, R. and Weiland, O. (1991) Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058-1061.
97. Richman, D.D. (1993) Playing chess with reverse transcriptase. Nature 361, 588-589.
98. Richman, D.D., Grimes, J.M. and Lagakos, S.W. (1990) Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 3, 743-746.
99. Richman, D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.A., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Shih, C.-K., Myers, M. and Griffin, J. (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68, 1660-1666.
100. Rubin, R.H., Lynch, P., Pasternack, M.S., Schoenfeld, D. and Medearis, D.N. (1989) Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob. Agents Chemother. 33, 1975-1979.
101. Rusconi, S., Merrill, D.P. and Hirsch, M.S. (1994) Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J. Infect. Dis. 170, 1361-1366.
102. Sahai, J., Gallicano, K., Pakuts, A. and Cameron, D.W. (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 169, 1103-1107.
103. Schapiro, J.M., Winters, M. and Merigan, T.C. (1995). Mutational analysis of the saquinavir high dose monotherapy study. IVth International Workshop on HI Drug-resistance, Sardinia. Abstract 73.
104. Schinazi, R.F. (1986) Drug combinations for treatment of mice infected with acyclovir-resistant herpes simplex virus. Antimicrob. Agents Chemother. 31, 477-479.
105. Schinazi, R.F., Peters, J., Williams, C.C., Chance, D. and Nahmias, A.J. (1982) Effect of combinations of acyclovir with vidarabin or its 5′-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob. Agents Chemother. 22, 499-507.
106. Schooley, R.T., Ramirez-Ronda, C., Lange, J.M.A., Cooper, D.A., Lavelle, J., Lefkowitz, L., Moore, M., Larder, B.A., St. Clair, M., Mulder, J.W., McKinnan, R., Pennington, K., Harrigan, P.R., Kinghorn, I., Skol, M., Rooney, J.F. and the Wellcome Resistance Study Collaborative Group (1995) Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared to zidovudine monotherapy. J. Infect. Dis. in press.
107. Schuurman, R., Nijhuis, M., Van leeuwen, R., Schipper, P., Collis, P., Danner, S., Mulder, J., Loveday, C., Christopherson, C., Kwok, S., Sninsky, J. and Boucher, C. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine. J. Infect. Dis. 171, 1431-1437.
108. Shaw, T., Amor, P., Civitico, G., Boyd, M. and Locarnini, S. (1994) In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38, 719-723.
109. Sim, S.M., Back, D.J. and Breckenridge, A.M. (1991) The effect of various drugs on the glucuronidation of zidovudine (azidothymidine, AZT) by human liver microsomes. Br. J. Clin. Pharmacol. 32, 17-21.
110. Stals, F., Wagenaar, S.S. and Bruggeman, C.A. (1994) Generalized cytomegalovirus (CMV) infection and CMV-induced pneumonitis in the rat: combined effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and specific antibody treatment. Antiviral Res. 25, 147-160.
111. Stretcher, B.N., Pesce, A.J., Frame, P.T. and Stein, D.S. (1994) Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38, 1541-1547.
112. Studies on Ocular Complications of AIDS Research Group (1994) Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophtalmology 101, 1250-1261.
113. Tisdale, M., Kemp, S.D., Parry, N.R. and Larder, B.A. (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90, 5653-5656.
114. Tyrrell, D.L.J., Fischer, K., Savani, K., Tan, W. and Jewell, L. (1993) Treatment of chimpanzees and ducks with lamivudine, 2′,3′ dideoxy 3′ thiacytidine, results in a rapid suppression of hepaviral DNA in sera. Clin. Invest. Med. 16 (suppl. 4), B77.
115. Van Leeuwen, R., Katlama, C., Kitchen, V., Boucher, C.A.B., Tubiana, R., Weber, J., Igrand, D., Hill, A. and Danner, S.A. (1995) Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171, 1166-1171.
116. Varagona, G., Brown, D., Kibbler, H., Scheuer, P., Ashrafzadeh, P., Sherlock, S., McIntyre, N. and Dusheiko, G. (1992) Response, relapse and retreatment rates and viraemia in chronic hepatitis C treated with alfa 2b interferon. A phase III study. Eur. J. Gastroent. and Hepatol. 4, 707-712.
117. Viner, K.C., Cammack, N., Coates, J.A., Hooker, E.U., Rouse, P., Penn, C.R. and Cameron, J.M. (1993). (-)enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in combination with AZT synergistically inhibits clinical isolates of HIV-1. IXth International Conference on AIDS, Berlin. Abstract PO-A25-0607.
118. Vogt, M.W., Hartshorn, K.L., Furman, P.A., Chou, T.-C., Fyfe, J.A., Coleman, L.A., Crumpacker, C., Schooley, R.T. and Hirsch, M.S. (1986) Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235, 1376-1379.
119. Wang, Y., Luscombe, C., Bowden, S., Shaw, T. and Locarnini, S. (1995) Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovirnalidixic acid. Antimicrob. Agents Chemother. 39, 556-558.
120. Weinberg, D.V., Murphy, R. and Naughton, K. (1994) Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. Am. J. Ophtalmol. 117, 776-782.
121. Whimbey, I.E., Champlin, R., Couch, R., Englund, J., Piedra, P., Mirza, N., Lewis, V., Goodrich, J. and Bodey, G.P. (1994). Respiratory syncytial virus (RSV) disease in adult BMT recipients: combination therapy with aerosolized ribavirin and high-titered IVIG. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando. Abstract H37.
122. Wright, H.I., Gavaler, J.S., Baddour, N. and Van Thiel, D.H. (1994) Granulocyte colony stimulating factor (G-CSF) combined with alpha-interferon for the treatment of liver allograft recipients with viral hepatitis. J. Hepatol. 21, 915-916.
123. Yamada, G., Takahashi, M., Tsuji, T., Yoshizawa, H. and Okamoto, H. (1992) Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis C. Dig. Dis. Sci. 37, 1926-1927.
124. Yeni, P. for the International Coordinating Committee (1995) Preliminary results of the European/Australian DELTA trial: based on data up to 31st May, 1995. 5th European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen. Late-breaker abstract.
125. Zeidner, N.S., Myles, M.H., Mathiason-DuBornack, M., Dreitz, M.J., Mullins, J.I. and Hoover, E.A. (1990a) Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob. Agents Chemother. 34, 1749-1756.
126. Zeidner, N.S., Rose, L.M., Mathiason-DuBard, C.K., Myles, M.H., Hill, D.L., Mullins, J.I. and Hoover, E.A. (1990a) Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J. Acquir. Immune Defic. Syndr. 3, 787-796.